Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZN-d5 · 3 trials · 5 indications
Incidence and severity of adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0
Incidence of Dose-limiting toxicities (DLTs) observed in DLT evaluable subjects
Maximum concentration (Cmax)
Observed Dose Limiting Toxicities (DLTs) in DLT-evaluable subjects.
Safety profile of ZN-d5.
| Arm | Type | Description |
|---|---|---|
| Treatment Arm | EXPERIMENTAL | Subjects will receive ZN-d5 orally (PO), once (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
| Healthy Volunteer | EXPERIMENTAL | Healthy Volunteer |
| ZN-d5 Single Agent Dose Escalation - NHL | EXPERIMENTAL | Non-Hodgkin Lymphoma |
| ZN-d5 Single Agent Dose Escalation - AML | EXPERIMENTAL | Acute Myeloid Leukemia |
| Name | Type | Description |
|---|---|---|
| ZN-d5 | DRUG | ZN-d5 will be administered orally |
Key Inclusion Criteria: 1. Diagnosis of AL amyloidosis based on histopathology, the presence of characteristic appearance on electron microscopy, or mass spectrometry typing of amyloid. 2. Prior AL amyloidosis treatment and has received at least one, but no more than three lines of prior therapy; 3...
ZN-d5 is an investigational small molecule being studied for the treatment of Acute Myeloid Leukemia, Non Hodgkin Lymphoma, and AL Amyloidosis. It has also been evaluated in healthy volunteers in food effect studies. The drug is in clinical development by Zentalis Pharmaceuticals.
ZN-d5 is a small molecule therapeutic developed by Zentalis Pharmaceuticals. The specific molecular target of ZN-d5 has not been disclosed in available clinical trial information. The drug is being investigated for its potential activity in hematologic malignancies and amyloidosis.
ZN-d5 is being developed by Zentalis Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol ZNTL. The company is conducting clinical trials to evaluate the safety and efficacy of ZN-d5 in patients with certain cancers and amyloidosis.
ZN-d5 is in Phase 1 clinical development. All three clinical trials listed for ZN-d5 are Phase 1 studies and have been completed. The drug remains investigational and has not been approved by regulatory authorities for any indication.
ZN-d5 has been studied in three completed Phase 1 clinical trials: NCT04500587, a first-in-human study in Acute Myeloid Leukemia and Non Hodgkin Lymphoma; NCT04854174, a food effect study in healthy female volunteers; and NCT05199337, a Phase 1/2 study in relapsed or refractory AL Amyloidosis.
ZN-d5 is the investigational name used by Zentalis Pharmaceuticals for this drug candidate. No alternative names have been disclosed in the clinical trial records. The drug is identified solely as ZN-d5 in the studies registered on ClinicalTrials.gov.